Anthony R Cillo1, Benedict B Hilldorfer, Christina M Lalama, John E McKinnon, Robert W Coombs, Allan R Tenorio, Lawrence Fox, Rajesh T Gandhi, Heather Ribaudo, Judith S Currier, Roy M Gulick, Timothy J Wilkin, John W Mellors. 1. aDivision of Infectious Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania bCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts cDivison of Infectious Diseases, Department of Medicine, Henry Ford Hospital, Detroit, Michigan dDepartment of Laboratory Medicine and Medicine, School of Medicine, University of Washington, Seattle, Washington eDepartment of Medicine, Rush University Medical Center, Chicago, Illinois fHIV Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland gDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts hDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California iDivision of Infectious Diseases, Weill Medical College, Cornell University, New York, New York, USA.
Abstract
BACKGROUND: Combination antiretroviral therapy (ART) suppresses HIV-1 replication, but does not restore CD4 T-cell counts in all individuals. To investigate the effects of maraviroc on HIV-1 persistence and the relations between virologic and immunologic parameters in individuals with incomplete CD4 T-cell recovery, we performed a prospective, open-label pilot trial in which maraviroc was added to a suppressive ART regimen for 24 weeks. DESIGN: A5256 was a single-arm trial in which individuals on suppressive ART with incomplete CD4 T-cell recovery added maraviroc for 24 weeks. METHODS: We quantified low-level, residual viremia in plasma and total HIV-1 DNA and 2-long terminal repeat (2-LTR) circles in peripheral blood mononuclear cells before and after maraviroc intensification. We also evaluated markers of CD4 and CD8 T-cell immune activation (%CD38HLA-DR) and apoptosis (%caspase3/Bcl-2). RESULTS: No effect of maraviroc was found on the probability of detectable plasma viremia (≥1 copy/ml; n = 31, exact McNemar P = 1.0) or detectable 2-LTR circles (n = 28, P = 0.25) or on total HIV-1 DNA (n = 28, 90% confidence interval -0.1, +0.3 log10 copies/10 CD4 T-cells). Premaraviroc HIV-1 DNA levels were inversely related to premaraviroc %CD38HLA-DR CD4 T-cells (Spearman = -0.52, P = 0.004), and lower premaraviroc HIV-1 DNA levels were associated with larger decreases in %CD38HLA-DR CD4 T-cells during maraviroc intensification (Spearman = 0.44, P = 0.018). CONCLUSION: In individuals on suppressive ART with incomplete CD4 T-cell recovery, maraviroc intensification did not affect measures of HIV-1 persistence but did decrease persistent CD4 T-cell immune activation especially in individuals with low preintensification levels of HIV-1 DNA.
BACKGROUND: Combination antiretroviral therapy (ART) suppresses HIV-1 replication, but does not restore CD4 T-cell counts in all individuals. To investigate the effects of maraviroc on HIV-1 persistence and the relations between virologic and immunologic parameters in individuals with incomplete CD4 T-cell recovery, we performed a prospective, open-label pilot trial in which maraviroc was added to a suppressive ART regimen for 24 weeks. DESIGN: A5256 was a single-arm trial in which individuals on suppressive ART with incomplete CD4 T-cell recovery added maraviroc for 24 weeks. METHODS: We quantified low-level, residual viremia in plasma and total HIV-1 DNA and 2-long terminal repeat (2-LTR) circles in peripheral blood mononuclear cells before and after maraviroc intensification. We also evaluated markers of CD4 and CD8 T-cell immune activation (%CD38HLA-DR) and apoptosis (%caspase3/Bcl-2). RESULTS: No effect of maraviroc was found on the probability of detectable plasma viremia (≥1 copy/ml; n = 31, exact McNemar P = 1.0) or detectable 2-LTR circles (n = 28, P = 0.25) or on total HIV-1 DNA (n = 28, 90% confidence interval -0.1, +0.3 log10 copies/10 CD4 T-cells). Premaraviroc HIV-1 DNA levels were inversely related to premaraviroc %CD38HLA-DR CD4 T-cells (Spearman = -0.52, P = 0.004), and lower premaraviroc HIV-1 DNA levels were associated with larger decreases in %CD38HLA-DR CD4 T-cells during maraviroc intensification (Spearman = 0.44, P = 0.018). CONCLUSION: In individuals on suppressive ART with incomplete CD4 T-cell recovery, maraviroc intensification did not affect measures of HIV-1 persistence but did decrease persistent CD4 T-cell immune activation especially in individuals with low preintensification levels of HIV-1 DNA.
Authors: B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch Journal: Science Date: 1997-07-04 Impact factor: 47.728
Authors: John A Bartlett; Michael J Fath; Ralph Demasi; Ashwaq Hermes; Joseph Quinn; Elsa Mondou; Franck Rousseau Journal: AIDS Date: 2006-10-24 Impact factor: 4.177
Authors: S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl Journal: N Engl J Med Date: 1997-09-11 Impact factor: 91.245
Authors: Steven A Yukl; Sara Gianella; Elizabeth Sinclair; Lorrie Epling; Qingsheng Li; Lijie Duan; Alex L M Choi; Valerie Girling; Terence Ho; Peilin Li; Katsuya Fujimoto; Harry Lampiris; C Bradley Hare; Mark Pandori; Ashley T Haase; Huldrych F Günthard; Marek Fischer; Amandeep K Shergill; Kenneth McQuaid; Diane V Havlir; Joseph K Wong Journal: J Infect Dis Date: 2010-10-12 Impact factor: 5.226
Authors: Nicholas Funderburg; Magdalena Kalinowska; James Eason; James Goodrich; Jayvant Heera; Howard Mayer; Natasa Rajicic; Hernan Valdez; Michael M Lederman Journal: PLoS One Date: 2010-10-06 Impact factor: 3.240
Authors: Guillaume J Besson; Christina M Lalama; Ronald J Bosch; Rajesh T Gandhi; Margaret A Bedison; Evgenia Aga; Sharon A Riddler; Deborah K McMahon; Feiyu Hong; John W Mellors Journal: Clin Infect Dis Date: 2014-07-29 Impact factor: 9.079
Authors: M L Gougeon; H Lecoeur; A Dulioust; M G Enouf; M Crouvoiser; C Goujard; T Debord; L Montagnier Journal: J Immunol Date: 1996-05-01 Impact factor: 5.422
Authors: Antoine Chaillon; Sara Gianella; Steven M Lada; Josué Perez-Santiago; Parris Jordan; Caroline Ignacio; Maile Karris; Douglas D Richman; Sanjay R Mehta; Susan J Little; Joel O Wertheim; Davey M Smith Journal: J Virol Date: 2018-01-17 Impact factor: 5.103
Authors: Susanna L Lamers; Gary B Fogel; Enoch S Liu; Marco Salemi; Michael S McGrath Journal: AIDS Res Hum Retroviruses Date: 2016-06-01 Impact factor: 2.205
Authors: Ian McGowan; Timothy Wilkin; Raphael J Landovitz; Chunyuan Wu; Ying Chen; Mark A Marzinke; Craig W Hendrix; Paul Richardson; Susan H Eshleman; Adriana Andrade; Wairimu Chege; Peter L Anderson; Marybeth McCauley; Jason Farley; Kenneth H Mayer; Peter Anton; Rhonda M Brand; Ross D Cranston; Roy Gulick Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Kevin R Robertson; Sachiko Miyahara; Anthony Lee; Todd T Brown; Ellen S Chan; Baiba Berzins; David Rusin; Joseph J Eron; Babafemi O Taiwo Journal: AIDS Date: 2016-09-24 Impact factor: 4.177